Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow MARIZYME, INC.

Get SEC filing alerts via email and in your feed for MARIZYME, INC.

MRZM

MARIZYME, INC.

About MARIZYME, INC.

Marizyme, Inc. is a medical technology company specializing in innovative solutions for cardiac care, notably developing and commercializing DuraGraft, an FDA-approved intra-operative vascular graft preservation product used in coronary artery bypass surgeries. The company focuses on expanding its global market presence, leveraging clinical data and strategic partnerships, while also developing technologies for fat grafting and kidney disease assessment. Its core strengths include patented products, regulatory approvals, and a focus on improving surgical outcomes.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from MARIZYME, INC.

1
1
MARIZYME, INC. Marizyme Reports No Revenue and Significant Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments